CMS Portugal advised the Amethyst Group, a leading international group in the healthcare sector, on its first investment in Portugal, with the acquisition of Júlio Teixeira S.A., a prominent Portuguese company in the field of nuclear medicine and radiotherapy, recognised for its innovation and clinical excellence.
To advise on this transaction, CMS Portugal relied on its Corporate M&A team, led by Partner Francisco Xavier de Almeida, with the participation of Managing Associate David Apolónia and Associate Francisca Pereira da Cruz.
Financial advice was provided by Banco Finantia, represented by Narciso Melo, Managing Director of Corporate Finance, and Diogo Lemos, Director of M&A and Corporate Finance.
The seller was advised by partners Jorge Simões Cortez and Constança Carrington, with the participation of associate Tiago Ribeiro dos Santos, from the Corporate M&A department of Morais Leitão, Galvão Teles, Soares da Silva & Associados. It also received financial advice from PwC, with José Pedro Ferreira, Director of Strategy & Corporate Finance, Maria Inês Enes, Manager, and Diogo Nunes, Senior Consultant.
According to Francisco Xavier de Almeida, Corporate M&A Partner at CMS Portugal: ‘We were very enthusiastic about advising the Amethyst Group on its first investment in Portugal. This transaction demonstrates the attractiveness of the Portuguese market to international investors and highlights CMS as the partner of choice to support the entry of new players into our country.’
